GW Pharmaceuticals Plc (GWPH) : On Thursday, The money flowed into the GW Pharmaceuticals Plc (GWPH) stock with an uptick to downtick ratio was recorded at 1.27. Transactions worth $2.32 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $1.83 million. The total money flow into the stock was $0.49 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.1 million of block transactions on upticks. The total money flow in block trades was $0.1 million. In terms of price action, GW Pharmaceuticals Plc (GWPH) traded down $0.52 during the session at $91.74. Compared to the previous days closing, the stock was down only by -0.56%. For the week, the stock is -3.26%, over previous weeks closing.
The stock has recorded a 20-day Moving Average of 0.3% and the 50-Day Moving Average is 4.44%. Shares have dropped -25.32% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $131.25 and the one year low was seen on Mar 10, 2016. The 50-Day Moving Average price is $90.01 and the 200 Day Moving Average price is recorded at $70.92.
GW Pharmaceuticals Plc (NASDAQ:GWPH): The stock opened at $92.75 on Thursday but the bulls could not build on the opening and the stock topped out at $92.98 for the day. The stock traded down to $90.21 during the day, due to lack of any buying support eventually closed down at $91.00 with a loss of -1.37% for the day. The stock had closed at $92.26 on the previous day. The total traded volume was 607,020 shares.
GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines, including Sativex for the treatment of multiple sclerosis spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. The Companys product, Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain, the indication for the United States market.